These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16749540)

  • 21. Acute suicidality after commencing atomoxetine.
    Paxton GA; Cranswick NE
    J Paediatr Child Health; 2008 Oct; 44(10):596-8. PubMed ID: 19012633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
    Simpson D; Plosker GL
    CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
    Ruggiero S; Rafaniello C; Bravaccio C; Grimaldi G; Granato R; Pascotto A; Sportiello L; Parretta E; Rinaldi B; Panei P; Rossi F; Capuano A
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation.
    Tang CS; Chou WJ; Cheng AT
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):319-20. PubMed ID: 19519271
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
    Camporeale A; Porsdal V; De Bruyckere K; Tanaka Y; Upadhyaya H; Deix C; Deberdt W
    J Psychopharmacol; 2015 Jan; 29(1):3-14. PubMed ID: 25424623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
    Prasad S; Harpin V; Poole L; Zeitlin H; Jamdar S; Puvanendran K;
    Curr Med Res Opin; 2007 Feb; 23(2):379-94. PubMed ID: 17288692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
    Holzer B; Lopes V; Lehman R
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
    Prasad S; Steer C
    Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atomoxetine-induced mydriasis.
    Alhatem FJ; Decker DH
    J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):539-41. PubMed ID: 18928421
    [No Abstract]   [Full Text] [Related]  

  • 30. Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.
    Wehmeier PM; Dittmann RW; Schacht A; Minarzyk A; Lehmann M; Sevecke K; Lehmkuhl G
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):813-30. PubMed ID: 18315453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
    Cunill R; Castells X; Tobias A; Capellà D
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):961-9. PubMed ID: 23813665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine.
    Bangs ME; Tauscher-Wisniewski S; Polzer J; Zhang S; Acharya N; Desaiah D; Trzepacz PT; Allen AJ
    J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):209-218. PubMed ID: 18176331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function.
    Shibao C; Raj SR; Gamboa A; Diedrich A; Choi L; Black BK; Robertson D; Biaggioni I
    Hypertension; 2007 Jul; 50(1):47-53. PubMed ID: 17515448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
    Troost PW; Steenhuis MP; Tuynman-Qua HG; Kalverdijk LJ; Buitelaar JK; Minderaa RB; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):611-9. PubMed ID: 17069549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of severe akathisia with atomoxetine.
    Baweja R; Petrovic-Dovat L
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):426-7. PubMed ID: 23952192
    [No Abstract]   [Full Text] [Related]  

  • 36. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
    Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Electroencephalographic study of children with attention deficit hyperactivity disorder before and after treatment with strattera].
    Nikishina IS; Chutko LS; Surushina SIu; Iakovenko EA; Kropotov IuD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(12):60-2. PubMed ID: 19253469
    [No Abstract]   [Full Text] [Related]  

  • 39. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
    Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
    Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
    CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.